It's not like this hasn't already been tried and failed miserably. http://www.bbc.com/news/techno... A quote from the article, "In August 2012 West Midlands Police said of 1,618 alerts produced by the system since November 2011, only two were confirmed gunfire incidents. What's more, the force added, ShotSpotter had also missed four confirmed shootings."
I hate to be the one to defend Facebook but they're doing nothing of the sort. If your post is flagged/reported by someone that reads it as selling a regulated product, not just a firearm, then the poster gets a notification reminding them to comply with applicable laws. The only thing they're really doing is interpreting statements like "no background check required" as a sign that the poster might be willing to help evade the law. They're not requiring the poster to perform a background check, they're just don't want the lack there of to be a selling point. This story is making a mountain out of an anthill.
I'm not saying I'd trust them either, but it is hard to determine how successful your program is if you don't get some kind of feedback. Seven years does seem excessive, but without knowing the results of the program, they can't modify it to be more effective.
The NFA was amended so you'd still be fine as long as you didn't cut it down to less than 16". But yes, constructive possession can be a very slippery slope.
Amazingly I got spam, I'm assuming because of this, just 5 minutes ago. Saying my profile picture is cute and they want to chat on yahoo messenger. Except for that fact that my picture is the retarded kid from the Stargate movie.
Rechargeable lithium-ion batteries, the most popular energy source for mobile electronic devices, are rapidly expanding their range of applications into fields such as electrical vehicles, grid energies, and flexible electronic devices.1 This strong market demand stimulates the need for development of advanced lithium ion battery technologies capable of improving energy storage densities, cycle life, charge/discharge rates, and design flexibility.2, 3
One strategy to address certain of these goals involves advanced structural design in the electrodes, along with associated new material development. For example, three dimensional (3D) electrodes can yield improvements in rate capability and capacity retention.4–6 These advantages are further enhanced in high-capacity anode materials, such as silicon and tin, which undergo large changes in volume during charge/discharge cycling.7, 8 One challenge for 3D electrodes, particularly in integration of active components, arises from difficulties in securing conformal electrolytes that can also prevent electrical shorts between electrodes.6 Although liquid electrolytes ensure excellent electrochemical performance and good physical contact with 3D electrodes, they suffer from potential leakage, leading to safety concerns. More importantly, liquid electrolytes limit choices in cell design due to their fluidic characteristics and the need for separator membranes in cell assembly. This situation motivates the development of self-supporting solid-state electrolytes that can conform to 3D electrodes and, at the same time, provide sufficient mechanical deformability for reliable use, especially for applications in flexible electronics and other demanding areas of envisioned use.
Among various solid-state electrolytes, gel polymer electrolytes (GPEs), which are generally composed of polymer matrix and liquid electrolyte, are widely used in lithium-ion batteries owing to their excellent ionic conductivity, low rates of safety failure, and mechanical flexibility.9–11 In general, conventional GPEs are prepared using a predesigned frame via solution casting of liquid state mixtures (i.e., liquid electrolytes and polymers dissolved in organic solvents or liquid electrolytes/polymerizable monomers), followed by solvent evaporation or chemical cross-linking for solidification. The initial, liquid-state, mixtures for GPEs have limited dimensional stability before solidification due to their intrinsically fluidic characteristics, thereby restricting their facile application to complex-structured systems such as 3D batteries.
To the best of our knowledge, there are no polymer electrolytes that are both shape-conformable to 3D electrodes and mechanically flexible without impairing their electrochemical performance. Moreover, it is still challenging to secure dimensional stability (as a solid form) of polymer electrolytes during electrolyte preparation and cell assembly process.6, 12
In the following, we demonstrate a facile and scalable approach to the fabrication of highly ion-conductive and bendable polymer electrolytes that can be also conformable to 3D micropatterned architectures of electrodes over large areas. These polymer electrolytes can also be directly writable or printable onto substrates of interest (including electrodes with complex geometries) due to well-tuned rheological characteristics. The materials are a kind of composite gel polymer electrolyte (hereinafter, referred to as “c-GPE”), composed of a UV (ultraviolet)-cured ethoxylated trimethylolpropane triacrylate (ETPTA) polymer matrix, high-boiling point liquid electrolyte (1M LiPF6 in ethylene carbonate (EC)/propylene carbonate (PC) = 1/1 (v/v)), and alumina (Al2O3) nanoparticles (Figure 1a). The ETPTA monomer, which contains trivalent vinyl groups that participate in UV-crosslinking,13, 14 serves as a mechanical framework (after UV-curing). The chemical structure of the ETPTA, along with 2-hydroxy-2-methyl-1-phenyl-1-propanon (HMPP, a photo-initiator), appears in Figure S1 in E
I have to say, Midco is amazing compared to what I had available in NJ. I'm getting 30/5 here for less than I would have gotten 10/1 from PTD back home.
Efforts over the past decade to characterize the genetic alterations in human cancers have led to a better understanding of molecular drivers of this complex set of diseases. Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low1. Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas. Given the high unmet need in oncology, it is understandable that barriers to clinical development may be lower than for other disease areas, and a larger number of drugs with suboptimal preclinical validation will enter oncology trials. However, this low success rate is not sustainable or acceptable, and investigators must reassess their approach to translating discovery research into greater clinical success and impact.
Many factors are responsible for the high failure rate, notwithstanding the inherently difficult nature of this disease. Certainly, the limitations of preclinical tools such as inadequate cancer-cell-line and mouse models2 make it difficult for even the best scientists working in optimal conditions to make a discovery that will ultimately have an impact in the clinic. Issues related to clinical-trial design — such as uncontrolled phase II studies, a reliance on standard criteria for evaluating tumour response and the challenges of selecting patients prospectively — also play a significant part in the dismal success rate3.
S. GSCHMEISSNER/SPL
Many landmark findings in preclinical oncology research are not reproducible, in part because of inadequate cell lines and animal models.
Unquestionably, a significant contributor to failure in oncology trials is the quality of published preclinical data. Drug development relies heavily on the literature, especially with regards to new targets and biology. Moreover, clinical endpoints in cancer are defined mainly in terms of patient survival, rather than by the intermediate endpoints seen in other disciplines (for example, cholesterol levels for statins). Thus, it takes many years before the clinical applicability of initial preclinical observations is known. The results of preclinical studies must therefore be very robust to withstand the rigours and challenges of clinical trials, stemming from the heterogeneity of both tumours and patients.
Confirming research findings The scientific community assumes that the claims in a preclinical study can be taken at face value — that although there might be some errors in detail, the main message of the paper can be relied on and the data will, for the most part, stand the test of time. Unfortunately, this is not always the case. Although the issue of irreproducible data has been discussed between scientists for decades, it has recently received greater attention (see go.nature.com/q7i2up) as the costs of drug development have increased along with the number of late-stage clinical-trial failures and the demand for more effective therapies.
Over the past decade, before pursuing a particular line of research, scientists (including C.G.B.) in the haematology and oncology department at the biotechnology firm Amgen in Thousand Oaks, California, tried to confirm published findings related to that work. Fifty-three papers were deemed 'landmark' studies (see 'Reproducibility of research findings'). It was acknowledged from the outset that some of the data might not hold up, because papers were deliberately selected that described something completely new, such as fresh approaches to targeting cancers or alternative clinical uses for existing therapeutics. Nevertheless, scientific findings were confirmed in only 6 (11%) cases. Even knowing the limitations of preclinical research, this was a shocking result.
Table 1: Reproducibility of research findings Preclinical research generates many secondary publications, even when results cannot be reproduced. Full table Of course, the validation attempts may have f
Slashdot Mirror
I did a quick google, http://www.businessinsider.com... was the first to pop up.
Between Samsung and Ikea putting their support behind the Qi standard, maybe we'll finally be able to declare a winner?
Could we find a smaller Nintendo logo? There current one is just too big.
It's not like this hasn't already been tried and failed miserably. http://www.bbc.com/news/techno...
A quote from the article, "In August 2012 West Midlands Police said of 1,618 alerts produced by the system since November 2011, only two were confirmed gunfire incidents. What's more, the force added, ShotSpotter had also missed four confirmed shootings."
I've heard some people are having framerate issues running SLI, so no rush on fixing the fan.
OMG have you thought your question through? He got it from the article.
I hate to be the one to defend Facebook but they're doing nothing of the sort. If your post is flagged/reported by someone that reads it as selling a regulated product, not just a firearm, then the poster gets a notification reminding them to comply with applicable laws. The only thing they're really doing is interpreting statements like "no background check required" as a sign that the poster might be willing to help evade the law. They're not requiring the poster to perform a background check, they're just don't want the lack there of to be a selling point. This story is making a mountain out of an anthill.
I'm not saying I'd trust them either, but it is hard to determine how successful your program is if you don't get some kind of feedback. Seven years does seem excessive, but without knowing the results of the program, they can't modify it to be more effective.
Not only that, but if you're in an accident it's going to take even longer to get to a hospital.
"Those who give up dignity for high-speed internet deserve neither."
- Ben Franklin 1775
The NFA was amended so you'd still be fine as long as you didn't cut it down to less than 16". But yes, constructive possession can be a very slippery slope.
Amazingly I got spam, I'm assuming because of this, just 5 minutes ago. Saying my profile picture is cute and they want to chat on yahoo messenger. Except for that fact that my picture is the retarded kid from the Stargate movie.
Rechargeable lithium-ion batteries, the most popular energy source for mobile electronic devices, are rapidly expanding their range of applications into fields such as electrical vehicles, grid energies, and flexible electronic devices.1 This strong market demand stimulates the need for development of advanced lithium ion battery technologies capable of improving energy storage densities, cycle life, charge/discharge rates, and design flexibility.2, 3
One strategy to address certain of these goals involves advanced structural design in the electrodes, along with associated new material development. For example, three dimensional (3D) electrodes can yield improvements in rate capability and capacity retention.4–6 These advantages are further enhanced in high-capacity anode materials, such as silicon and tin, which undergo large changes in volume during charge/discharge cycling.7, 8 One challenge for 3D electrodes, particularly in integration of active components, arises from difficulties in securing conformal electrolytes that can also prevent electrical shorts between electrodes.6 Although liquid electrolytes ensure excellent electrochemical performance and good physical contact with 3D electrodes, they suffer from potential leakage, leading to safety concerns. More importantly, liquid electrolytes limit choices in cell design due to their fluidic characteristics and the need for separator membranes in cell assembly. This situation motivates the development of self-supporting solid-state electrolytes that can conform to 3D electrodes and, at the same time, provide sufficient mechanical deformability for reliable use, especially for applications in flexible electronics and other demanding areas of envisioned use.
Among various solid-state electrolytes, gel polymer electrolytes (GPEs), which are generally composed of polymer matrix and liquid electrolyte, are widely used in lithium-ion batteries owing to their excellent ionic conductivity, low rates of safety failure, and mechanical flexibility.9–11 In general, conventional GPEs are prepared using a predesigned frame via solution casting of liquid state mixtures (i.e., liquid electrolytes and polymers dissolved in organic solvents or liquid electrolytes/polymerizable monomers), followed by solvent evaporation or chemical cross-linking for solidification. The initial, liquid-state, mixtures for GPEs have limited dimensional stability before solidification due to their intrinsically fluidic characteristics, thereby restricting their facile application to complex-structured systems such as 3D batteries.
To the best of our knowledge, there are no polymer electrolytes that are both shape-conformable to 3D electrodes and mechanically flexible without impairing their electrochemical performance. Moreover, it is still challenging to secure dimensional stability (as a solid form) of polymer electrolytes during electrolyte preparation and cell assembly process.6, 12
In the following, we demonstrate a facile and scalable approach to the fabrication of highly ion-conductive and bendable polymer electrolytes that can be also conformable to 3D micropatterned architectures of electrodes over large areas. These polymer electrolytes can also be directly writable or printable onto substrates of interest (including electrodes with complex geometries) due to well-tuned rheological characteristics. The materials are a kind of composite gel polymer electrolyte (hereinafter, referred to as “c-GPE”), composed of a UV (ultraviolet)-cured ethoxylated trimethylolpropane triacrylate (ETPTA) polymer matrix, high-boiling point liquid electrolyte (1M LiPF6 in ethylene carbonate (EC)/propylene carbonate (PC) = 1/1 (v/v)), and alumina (Al2O3) nanoparticles (Figure 1a). The ETPTA monomer, which contains trivalent vinyl groups that participate in UV-crosslinking,13, 14 serves as a mechanical framework (after UV-curing). The chemical structure of the ETPTA, along with 2-hydroxy-2-methyl-1-phenyl-1-propanon (HMPP, a photo-initiator), appears in Figure S1 in E
Those most be some really expensive cigarettes then.
"The coveted rifles they fled with from the Syrian military, worth at least $4,000 each on the black market, hang on nails driven into a dirty white wall."
Actually, provided it's a rifle or a shotgun it's perfectly legal as long as the laws of both states are followed. http://www.atf.gov/firearms/faq/unlicensed-persons.html#gca-unlicensed-acquire
Close, you're thinking of DGPS. WAAS is satellite based, just like EGNOS.
I have to say, Midco is amazing compared to what I had available in NJ. I'm getting 30/5 here for less than I would have gotten 10/1 from PTD back home.
That wasn't a whoosh, it was more like a http://www.youtube.com/watch?v=k4f3vJjvR9c
God damn Muphry's law...:-/
I think it's contagious. ;-)
Rest in peace, but is it too late to Fuck me, Ray Bradbury?
You should be able to see aliens french kissing on planets closer than 200 light years.
Dammit, it's Adam and Eve, not Adam and Gfkladjfane.
Efforts over the past decade to characterize the genetic alterations in human cancers have led to a better understanding of molecular drivers of this complex set of diseases. Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low1. Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas. Given the high unmet need in oncology, it is understandable that barriers to clinical development may be lower than for other disease areas, and a larger number of drugs with suboptimal preclinical validation will enter oncology trials. However, this low success rate is not sustainable or acceptable, and investigators must reassess their approach to translating discovery research into greater clinical success and impact.
Many factors are responsible for the high failure rate, notwithstanding the inherently difficult nature of this disease. Certainly, the limitations of preclinical tools such as inadequate cancer-cell-line and mouse models2 make it difficult for even the best scientists working in optimal conditions to make a discovery that will ultimately have an impact in the clinic. Issues related to clinical-trial design — such as uncontrolled phase II studies, a reliance on standard criteria for evaluating tumour response and the challenges of selecting patients prospectively — also play a significant part in the dismal success rate3.
S. GSCHMEISSNER/SPL
Many landmark findings in preclinical oncology research are not reproducible, in part because of inadequate cell lines and animal models.
Unquestionably, a significant contributor to failure in oncology trials is the quality of published preclinical data. Drug development relies heavily on the literature, especially with regards to new targets and biology. Moreover, clinical endpoints in cancer are defined mainly in terms of patient survival, rather than by the intermediate endpoints seen in other disciplines (for example, cholesterol levels for statins). Thus, it takes many years before the clinical applicability of initial preclinical observations is known. The results of preclinical studies must therefore be very robust to withstand the rigours and challenges of clinical trials, stemming from the heterogeneity of both tumours and patients.
Confirming research findings
The scientific community assumes that the claims in a preclinical study can be taken at face value — that although there might be some errors in detail, the main message of the paper can be relied on and the data will, for the most part, stand the test of time. Unfortunately, this is not always the case. Although the issue of irreproducible data has been discussed between scientists for decades, it has recently received greater attention (see go.nature.com/q7i2up) as the costs of drug development have increased along with the number of late-stage clinical-trial failures and the demand for more effective therapies.
Over the past decade, before pursuing a particular line of research, scientists (including C.G.B.) in the haematology and oncology department at the biotechnology firm Amgen in Thousand Oaks, California, tried to confirm published findings related to that work. Fifty-three papers were deemed 'landmark' studies (see 'Reproducibility of research findings'). It was acknowledged from the outset that some of the data might not hold up, because papers were deliberately selected that described something completely new, such as fresh approaches to targeting cancers or alternative clinical uses for existing therapeutics. Nevertheless, scientific findings were confirmed in only 6 (11%) cases. Even knowing the limitations of preclinical research, this was a shocking result.
Table 1: Reproducibility of research findings
Preclinical research generates many secondary publications, even when results cannot be reproduced.
Full table
Of course, the validation attempts may have f
I don't think anyone was confused that name was a knock off of Mass Effect.
Yeah, looking through his tweets this goes back at least a couple days, so I'm hopeful this isn't an extremely elaborate joke.
This sounded like such an awesome game idea until I saw:
© April 1 2012 Mojang
at the bottom of http://marseffect.net/